在患有长QT综合征的患者中进行双设备治疗
Shohei Kataoka1, Daigo Yagishita1,2, Kyoichiro Yazaki1
1Department of Cardiology Tokyo Women's Medical University Tokyo Japan.
Journal of arrhythmia
|June 28, 2024
概括
一名患有长QT综合征 (LQTS) 的患者经常受到皮下植入式心脏转换器-除器 (S-ICD) 的频繁冲击. 心脏起器植入和"双设备疗法"成功地管理了心室心律失常.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 医疗器械 医疗器械
背景情况:
- 长QT综合征 (LQTS) 是一种心脏通道病变,与心室心律不整的风险增加有关.
- 皮下植入式心脏转换器-除器 (S-ICD) 用于预防患有特定疾病的患者的突然心脏死亡.
- β-阻断剂是LQTS的第一线治疗方法,但在某些患者中可能会加剧心肌梗塞和QT延长.
研究的目的:
- 描述一个患有LQTS和心病的患者心室节律失常的病例.
- 在一个具有挑战性的LQTS病例中,评估S-ICD植入和随后的起器干预的疗效.
- 探索"双设备疗法"在预防LQTS患者患有设备相关并发症的心律失常方面的作用.
主要方法:
- 一名26岁的男性患有LQTS和鼻肌梗塞,接受了S-ICD植入.
- 用β-阻断剂进行药理管理导致QT间隔增加和S-ICD频繁放出.
- 植入了一个单腔起器,然后转换为"双设备治疗" (S-ICD和起器).
主要成果:
- 由于胸肌梗塞和延长的QT间隔,患者经常经历不适当的S-ICD放电.
- 心脏起器植入导致心房节奏,心室传感60bpm,以及更短的QTc间隔.
- 在过渡到"双设备治疗"后,患者仍然没有心室心律失常事件.
结论:
- 在LQTS患者中,S-ICD疗法可能具有挑战性,因为LQTS患者具有固有的胸.
- 心脏起器植入可以有效地管理心脏节,并减轻LQTS中不适当的S-ICD冲击.
- "双设备治疗"可能是选择的LQTS患者综合性心律失常管理的可行策略.
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
965
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
965
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
823
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
823
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
735
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
735
Electroconvulsive Therapy
31
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
31
Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564


